SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 13, 2007 (November 7, 2007)
(Exact Name of Registrant as Specified in Charter)
Delaware (State or Other Jurisdiction of Incorporation) | | 000-49730 (Commission File No.) | | 22-3374365 (IRS Employer Identification No.) |
150 Pierce Street, Somerset, NJ 08873
(Address of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, including Area Code: (732) 907-3600
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))
ITEM 2.02. RESULTS OF OPERATION AND FINANCIAL CONDITION.
On November 7, 2007, DOV Pharmaceutical, Inc. (“DOV” or the “Company”) announced its financial results for the quarter ended September 30, 2007. The press release issued in connection with such announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K.
Exhibit No. | Description |
| 99.1 | Press Release, dated November 7, 2007, of DOV Pharmaceutical, Inc. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | |
| | DOV PHARMACEUTICAL , INC. |
| | |
| Date: November 13 , 2007 | By: | /s/ Barbara Duncan |
| | Barbara Duncan Chief Executive Officer |
EXHIBIT INDEX
Exhibit No. | Description |
| 99.1 | Press Release, dated November 7, 2007, of DOV Pharmaceutical, Inc. |
